Open AccessPharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis
Author(s) -
A. Young J. Park,
Joshua Wang,
Jordanna G. Jayne,
Lynn Fukushima,
Adupa P. Rao,
David Z. D’Argenio,
Paul M. Beringer
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00550-18
Subject(s) - cystic fibrosis , sputum , pharmacokinetics , medicine , gastroenterology , pharmacology , tuberculosis , pathology
Over the past decade, the prevalence of infections involving methicillin-resistantStaphylococcus aureus (MRSA) in patients with cystic fibrosis (CF) has increased significantly. Tedizolid (TZD) demonstrates excellent activity against MRSA and a favorable safety profile.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom